Market Currents
AstraZeneca (AZN): Q2 sales -21% to $6.66B vs. $6.95B consensus. Core EPS -12% to $1.53 vs....
-
Thursday, July 26, 2012, 5:25 AM ETAstraZeneca (AZN): Q2 sales -21% to $6.66B vs. $6.95B consensus. Core EPS -12% to $1.53 vs. $1.39 consensus. Shares -2.5% premarket. (PR .pdf)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
